Modality
mRNA
MOA
CAR-T CD19
Target
BCL-2
Pathway
Proteasome
IPFCLL
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
Aug 2017
→ Jul 2025
Phase 1Current
NCT03840079
2,646 pts·IPF
2021-02→TBD·Active
NCT07528822
2,917 pts·CLL
2017-08→2025-07·Recruiting
5,563 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-07-198mo agoPh2 Data· CLL
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P1/2
Recruit…
P1/2
Active
Catalysts
Ph2 Data
2025-07-19 · 8mo ago
CLL
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03840079 | Phase 1/2 | IPF | Active | 2646 | PANSS |
| NCT07528822 | Phase 1/2 | CLL | Recruiting | 2917 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 | |
| Talasotorasib | Exelixis | Preclinical | APOC3 |